Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer
- 180 Downloads
We conducted a multicenter phase II trial assessing chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced, unresectable esophageal cancer. The aim of this study was to validate the concordance of clinical T diagnosis among physicians in the cases of this trial.
Computed tomography scans and esophagoscopic images of 48 patients taken at baseline were centrally reviewed by 6 senior physicians with experience in esophageal oncology. Individual reviewers voted for definitive T4, relative T4, relative T3, or definitive T3. Discordant diagnoses between reviewers were resolved by the majority opinion. The reviewers were blinded to patient clinical outcome data and to the vote of the other reviewers.
Ninety percent of cases were diagnosed as clinical T4 by investigators, while 33.3–75.0% (median 70.8%) of cases were judged to be T4 by 6 reviewers. Discordant diagnosis between investigators and reviewers occurred in 33% (16/48) of all cases (Cohen’s kappa coefficient 0.0519), including 12 cases where curative resection was considered possible (48%, n = 25) and 4 cases where curative resection was considered impossible (17%, n = 23). Critical discordance (one reviewer voted for definitive T3 but the other voted for definitive T4, and vice versa) between reviewers occurred in 0–12.5% of cases (median 2.1%).
There were inter-observer variations in clinical diagnosis of the T category of locally advanced, unresectable esophageal cancer. Accurate clinical diagnosis of T classification is required for determining the optimum treatment for each patient.
KeywordsEsophageal squamous cell carcinoma Clinical T diagnosis Central review Concordance
The authors are grateful to Tella Imaging Technology and Alliance Network (TITAN Inc.). This study was supported by Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (15652916). The authors are grateful to Dr. Takashi Ichimura, Dr. Mariko Ogura, Dr. Daisuke Takahari (Cancer Institute Hospital of Japanese Foundation for Cancer Research), Dr. Fumihiko Kato, Dr. Satoshi Matsuda (Keio University School of Medicine), Dr. Natsuko Okita, Dr. Satoru Iwasa, Dr. Atsuo Takashima, Dr. Yoshitaka Honma (National Cancer Center Hospital), Dr. Takako Yoshii (Saitama Cancer Center), Dr. Akiko Todaka, Dr. Nozomu Machida, Dr. Takahiro Tsushima (Shizuoka Cancer Center), Dr. Keiko Minashi (Chiba Cancer Center), Dr. Tetsushi Terasawa, Dr. Hitoshi Nishitani (Osaka Medical College), Dr. Kazuhiko Yamada (National Center for Global Health and Medicine), Dr. Kentaro Kawakami (Tochigi Cancer Center) for submission of CT scans and esophagoscopic images.
Compliance with ethical standards
Conflict of interest
Dr. Yuko Kitagawa has received research funding from Takeda Pharmaceutical Co., Ltd, Kyowa Hakko Kirin Co., Ltd, and Yakult Honsha Co., Ltd. Dr. Ken Kato has received research funding from ONO, MSD, and Shionogi.
- 5.NCCN Clinical Practice Guidelines in Oncology (2017), Esophageal and esophagogastric junction cancers, version 1Google Scholar
- 6.Yokota T, Kato K, Hamamoto Y et al (2016) Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Br J Cancer 115:1328–1334CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Sobin LH, Wittekind C (2009) TNM classification of malignant tumors (UICC), 7th edn, Wiley-Blackwell, UK. http://www.uicc.org/resources/tnm
- 12.Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74CrossRefPubMedGoogle Scholar